Meeting Report
2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline
Presented by Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP
From Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
Presenter’s disclosure of conflict of interest is found at the end of this article.
J Adv Pract Oncol 2023;14(3):237–240 |
https://doi.org/10.6004/jadpro.2023.14.3.11 |
© 2023 Harborside™
ABSTRACT
During JADPRO Live 2022, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechanism of action, a rethinking of how to approach treating a disease, or those that have recently received FDA Breakthrough Designation status that advanced practitioners should be aware of.
For access to the full length article, please
sign in.
